In cancer, RNA splicing is often dysregulated including by mutations in RNA splicing factors (RNA-SF), and inhibition of Type I PRMT and PRMT5 by MS023 and GSK591, respectively, has been shown to effectively target cells bearing RNA-SF mutations, both in vitro and in vivo (Fong et al. 2019). The gene discussed is PRMT5; the disease is cancer.